Article

Heart failure differs in patients with RA

The clinical presentation and outcome of heart failure differ significantly in patients who have rheumatoid arthritis (RA) and those who do not.The presentation of heart failure is more subtle in patients with RA, and mortality is significantly higher.

The clinical presentation and outcome of heart failure differ significantly in patients who have rheumatoid arthritis (RA) and those who do not.The presentation of heart failure is more subtle in patients with RA, and mortality is significantly higher.

Davis and associates conducted a community-based cohort study comparing 103 patients with RA and 852 patients without RA who had heart failure. They collected clinical data about the clinical presentation, echocardiographic data, and information on the use of medications (angiotensin-converting enzyme [ACE] inhibitors and β-blockers).

The patients with RA were less likely to present with paroxysmal nocturnal dyspnea, hepatojugular reflux, dyspnea on exertion, and orthopnea; significantly more likely to have rales; and far less likely to present with elevated systolic or diastolic blood pressure. They were less likely to have undergone echocardiography. Their mean ejection fraction was significantly higher. Patients with RA and heart failure received treatment with ACE inhibitors and β-blockers less frequently. Mortality was higher 30 days and 1 year after the onset of heart failure.

The authors noted that these findings emphasize the importance of more vigilant screening of patients who have RA for early signs of heart failure and may represent important insights into underlying mechanisms.

Related Videos
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment
© 2024 MJH Life Sciences

All rights reserved.